Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327754 | 0.86 | PPARG (0.56) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327593 | 0.86 | TP53 (0.58) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327620 | 0.85 | TP53 (0.54) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327616 | 0.83 | TP53 (0.56) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327625 | 0.83 | PPARG (0.60) | PPARGMAPTNPC1RAB9ATHRB | |
| SCHEMBL29327627 | 0.82 | MAPT (0.57) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327696 | 0.81 | TP53 (0.56) | PPARGPTGS2MAPTKDM4EALDH1A1 | |
| SCHEMBL29327637 | 0.81 | PPARG (0.52) | PPARGMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL29327646 | 0.80 | PPARG (0.53) | PPARGMAPTKDM4ENPC1RAB9A | |
| SCHEMBL29327828 | 0.80 | PPARG (0.56) | PPARGPTGS2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885PTGS2 368/4885MAPT 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.